Clinical Presentations, Laboratory and Endoscopic Findings, Treatment Patterns, and Early Outcomes of Pediatric Crohn’s Disease at a Tertiary Center in Tripoli, Libya:
DOI:
https://doi.org/10.54361/LJMR.20.1.22Keywords:
Crohn's disease, Paediatric; Inflammatory bowel disease, Growth parameters, Colonoscopy, Biological therapyAbstract
Background: Pediatric Crohn’s disease (CD) presents with variable gastrointestinal and systemic symptoms and is often diagnosed late. Objective: To describe the clinical characteristics, laboratory and endoscopic findings, treatment approaches, and early outcomes among children aged 3–15 years diagnosed with CD at a tertiary center in Libya.
Methods: A cross-sectional observational study using retrospectively collected data, the study was conducted at the Department of Pediatric Gastroenterology and Hepatology, Tripoli University Hospital, Tripoli, Libya, between 2023 and 2025 of 40 children diagnosed with CD. Data included demographics, clinical presentation, growth, labs, endoscopy, histopathology, treatment, and outcomes. Results: Diarrhea (97.5%), abdominal pain (95%), fever (90%), and weight loss (87.5%) were common. Growth impairment was seen in 72.5%. Lab abnormalities included anemia (85%), high CRP (95%), high ESR (80%), and low albumin (62.5%). Terminal ileum involvement was seen in 95%. All received steroids and azathioprine; 60% received Biological therapy. Remission achieved in 85%; relapses in 15%.
Conclusion: Pediatric CD in this cohort showed prolonged symptoms, growth impairment, and severe inflammation. Despite challenges, early remission was common with appropriate therapy. Improved early recognition and expanded access to diagnostics and biologics are essential.
Downloads
References
1. Ng SC, et al. Global variations and trends in inflammatory bowel disease incidence: A systematic review. Lancet. 2018;390(10114):2769–2778.
2. Levine A, et al. ESPGHAN Revised Porto Criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806.
3. Ruemmele FM, et al. Pediatric Crohn’s disease: Current management and future perspectives. J Crohns Colitis. 2023;17 (5):643–654.
4. Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers. Al-Beltagi M, Saeed NK, Mani PKC, Bediwy AS, Elbeltagi R.World J Gastroenterol. 2025 Sep 21;31(35).
5. Regional variation of pediatric inflammatory bowel disease in Saudi Arabia: Results from a multicenter study. Mohammad I El Mouzan, Ahmad A Al Sarkhy, Asaad A Assiri World J Gastroenterol 2020 Jan 28;26(4):416–423.
6. Bone Mineral Density in Patients with Pediatric Inflammatory Bowel Disease Using Dual Energy X-Ray Absorptiometry. Hasan M Isa , Amira A Ezzaldin , Mohamed M Alabbasi , Noora H Alaa'zmi , Abdulrahman S Masood , Hissa M Alabbasi . J Bone Metab. 2023 Feb 28;30(1):59–68.
7. Jin, H. Y., Lim, JS., Lee, Y. et al. Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease. BMC Pediatr 21, 35 (2021).
8. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology. 1988;95(6):1523-1527.
9. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 2006;118(1):124-129.
10. Growth failure in pediatric-onset inflammatory bowel disease: mechanisms, epidemiology, and management. Takashi Ishige, Translational pediatrics Vol 8, No 1 (January 28, 2019).
11. Chang JT: Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020, 383:2652-64.
12. Zhang H, Zeng Z, Mukherjee A, Shen B: Molecular diagnosis and classification of inflammatory bowel disease. Expert Rev Mol Diagn. 2018.
13. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A.Gastroenterology. 2019 Aug;157(2):320-348.
14. Ben Saleh FH. Challenges and advances in the diagnosis and management of pediatric inflammatory bowel disease: a systematic review. International Journal of Science and Technology (ISTJ). 2025 Apr.
15. Clark C, Turner J: Diagnostic modalities for inflammatory bowel disease: serologic markers and endoscopy. Surg Clin North Am. 2015, 95:1123-41.
16. Benchimol EI, et al. Epidemiology of pediatric inflammatory bowel disease: International perspectives. Gastroenterology. 2020; 159(4):1108–1124.
17. Kelsen JR, Baldassano RN. Inflammatory bowel disease: The difference between children and adults. Inflamm Bowel Dis. 2018; 24(5):952–962.
18. Chang JT: Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020, 383:2652-64.
19. Croft NM. Bridging the gap in drug approvals for pediatric IBD: A multi-stakeholder perspective. J Crohns Colitis. 2023.
20. Leonor R, Jacobson K, Pinsk K, Webber E, Lemberg DA. Surgical intervention in children with Crohn's disease. Int J Colorectal Dis 2007;22:1037-41.
21. IIRN Epidemiology cohort. Epidemiology of pediatric-onset perianal Crohn’s disease: epi-IIRN study. 2022.
22. Systematic review of anti-TNF-α therapy (infliximab and adalimumab) in pediatric perianal Crohn’s disease. 2019.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zinab Ashour Saad, Fathia Hameda Ben Saleh (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
https://portal.issn.org/resource/ISSN/2413-6069
